Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires Shares of 103,191 Scholar Rock Holding Corporation $SRRK

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the fourth quarter, HoldingsChannel reports. The fund bought 103,191 shares of the company’s stock, valued at approximately $4,546,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Three Seasons Wealth LLC boosted its holdings in shares of Scholar Rock by 2.1% in the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after acquiring an additional 222 shares during the period. Principal Financial Group Inc. raised its position in Scholar Rock by 7.9% in the 3rd quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after purchasing an additional 456 shares during the last quarter. California State Teachers Retirement System raised its position in Scholar Rock by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after purchasing an additional 577 shares during the last quarter. Tema Etfs LLC boosted its stake in Scholar Rock by 6.6% during the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock worth $436,000 after purchasing an additional 616 shares during the period. Finally, E Fund Management Co. Ltd. grew its position in Scholar Rock by 6.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company’s stock worth $395,000 after purchasing an additional 710 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on SRRK shares. Truist Financial raised their price target on Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Canaccord Genuity Group began coverage on Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target on the stock. Wedbush increased their price objective on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Five investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $56.00.

Scholar Rock Trading Up 1.7%

Shares of Scholar Rock stock opened at $48.38 on Thursday. The company has a 50-day moving average of $46.81 and a two-hundred day moving average of $44.25. Scholar Rock Holding Corporation has a 12-month low of $27.07 and a 12-month high of $51.63. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock has a market cap of $5.80 billion, a PE ratio of -13.48 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter last year, the firm posted ($0.67) earnings per share. On average, research analysts anticipate that Scholar Rock Holding Corporation will post -3.18 EPS for the current fiscal year.

Insider Activity

In other news, CEO David Hallal sold 30,615 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $1,517,585.55. Following the completion of the sale, the chief executive officer directly owned 1,639,034 shares in the company, valued at $81,246,915.38. The trade was a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the completion of the sale, the insider directly owned 630,542 shares of the company’s stock, valued at $31,255,966.94. The trade was a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 71,975 shares of company stock worth $3,546,591. 13.30% of the stock is owned by corporate insiders.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).